Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Inclusion criteria :

• Male or female aged 5 to 18 years old.
• Weight ≥15 kg.
• Chronic kidney disease (CKD) Stage 3 or 4 not on dialysis, defined as glomerularfiltration rate (GFR) between 15 and 59 mL/min/1.73m^2 (established by Schwartzequation) at Week -2 visit.
• Intact parathyroid hormone (iPTH) value >100 pg/mL for CKD Stage 3 or >160 pg/mL forCKD Stage 4, at Week -2 visit.
• Signed informed consent/assent form.

Exclusion criteria:

• The patient has a serum 25-hydroxyvitamin D level <30 ng/mL at screening.
• The patient has a corrected calcium ≥10 mg/dL at the Week -2 visit.
• The patient has a serum phosphorus >4.5 mg/dL for children 13 to 18 years of age; >5.8mg/dL for children 5 to 12 years of age at the Week -2 visit.
• The patient is anticipated to require maintenance hemodialysis within 3 months.
• The patient used cinacalcet or vitamin D sterol therapies such as calcitriol,doxercalciferol, or paricalcitol within 14 days prior to the baseline visit.
• The patient has a history of, or active, symptomatic heart disease within 12 monthsprior to the baseline (Week 0) visit.
• The patient currently has a chronic gastrointestinal disease (ie, malabsorption,severe chronic diarrhea, chronic ulcerative colitis, or ileostomy).
• The patient currently has primary hyperparathyroidism or has had a totalparathyroidectomy.
• The patient has an active malignancy.
• The patient is unable to swallow a capsule in size similar to the Hectorol® andRocaltrol® capsules.
• The patient has a history of sensitivity or allergy to doxercalciferol, calcitriol orother vitamin D analogs.
• The patient currently uses aluminum or magnesium-based binders. The above information is not intended to contain all considerations relevant to a patient'spotential participation in a clinical trial.